TCON Tracon Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: TCON

Price (delayed)

$1.86

Market cap

$4.23M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.2

Enterprise value

-$4.41M

TRACON develops targeted therapies for cancer utilizing a capital efficient, CRO independent, product development platform. The Company's clinical-stage pipeline includes: Envafolimab, a PD-L1 single-domain antibody given by rapid subcutaneous injection ...

Highlights
Tracon Pharmaceuticals's debt has plunged by 100% YoY
The EPS has soared by 92% YoY and by 81% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.traconpharma.com
Peers: AKBA AGEN ALDX

Key stats

What are the main financial stats of TCON
Market
Shares outstanding
2.28M
Market cap
$4.23M
Enterprise value
-$4.41M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
0.25
EV/EBIT
-1.19
EV/EBITDA
-1.17
EV/Sales
-0.37
Earnings
Revenue
$12.05M
EBIT
$3.72M
EBITDA
$3.75M
Free cash flow
$3.68M
Per share
EPS
-$2.2
Free cash flow per share
$2.25
Book value per share
-$0.52
Revenue per share
$7.36
TBVPS
$6.17
Balance sheet
Total assets
$10.11M
Total liabilities
$10.91M
Debt
$0
Equity
-$809,000
Working capital
-$1.09M
Liquidity
Debt to equity
0
Current ratio
0.89
Quick ratio
0.85
Net debt/EBITDA
-2.3
Margins
EBITDA margin
31.1%
Gross margin
100%
Net margin
-29.8%
Operating margin
-77%
Efficiency
Return on assets
-35.9%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
N/A
Return on sales
30.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

TCON stock price

How has the Tracon Pharmaceuticals stock price performed over time
Intraday
2.76%
1 week
2.76%
1 month
-57.63%
1 year
-87.26%
YTD
-46.89%
QTD
-78.36%

Financial performance

How have Tracon Pharmaceuticals's revenue and profit performed over time
Revenue
$12.05M
Gross profit
$12.05M
Operating income
-$9.27M
Net income
-$3.59M
Gross margin
100%
Net margin
-29.8%
Tracon Pharmaceuticals's net income has surged by 88% YoY and by 67% QoQ
Tracon Pharmaceuticals's net margin has soared by 76% from the previous quarter
The operating income has soared by 67% YoY and by 40% from the previous quarter
The operating margin has soared by 55% from the previous quarter

Growth

What is Tracon Pharmaceuticals's growth rate over time

Valuation

What is Tracon Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
0.25
EV/EBIT
-1.19
EV/EBITDA
-1.17
EV/Sales
-0.37
The EPS has soared by 92% YoY and by 81% from the previous quarter
TCON's equity has soared by 89% YoY and by 74% from the previous quarter
TCON's revenue is up by 34% since the previous quarter

Efficiency

How efficient is Tracon Pharmaceuticals business performance
The ROA has soared by 77% YoY and by 60% QoQ

Dividends

What is TCON's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TCON.

Financial health

How did Tracon Pharmaceuticals financials performed over time
TCON's total assets is 7% smaller than its total liabilities
The total liabilities has plunged by 59% YoY and by 13% from the previous quarter
TCON's total assets is down by 48% year-on-year but it is up by 7% since the previous quarter
Tracon Pharmaceuticals's debt is 100% more than its equity
The company's debt to equity has surged by 100% YoY
Tracon Pharmaceuticals's debt has plunged by 100% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.